Prognostic value of RASSF1 promoter methylation in prostate cancer

Journal of Urology

Volumn 192, Issue 6, 2014, Pages 1849-1855

  Daniunaite, Kristina ^a   Jarmalaite, Sonata ^a   Kalinauskaite, Neringa ^a   Petroska, Donatas ^a,b   Laurinavicius, Arvydas ^a,b   Lazutka, Juozas R ^a   Jankevicius, Feliksas ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

^b National Centre of Pathology   (Lithuania)

Author keywords

biological markers; DNA methylation; prostate; prostatic neoplasms; recurrence

Indexed keywords

DAPK1 PROTEIN; GLUTATHIONE TRANSFERASE P1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN; PROTEIN P14; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; UNCLASSIFIED DRUG; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DNA DETERMINATION; DNA METHYLATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE SEDIMENT; GENETICS; METABOLISM; PROGNOSIS; PROSTATE TUMOR;

DNA METHYLATION; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84913593944     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.06.075     Document Type: Article

References (22)

1. J. Ferlay, E. Steliarova-Foucher, and J. Lortet-Tieulent Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374
2. K.A. Roehl, M. Han, and C.G. Ramos Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results J Urol 172 2004 910
3. L. Spans, L. Clinckemalie, and C. Helsen The genomic landscape of prostate cancer Int J Mol Sci 14 2013 10822
4. H. Beltran, R. Yelensky, and G.M. Frampton Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity Eur Urol 63 2013 920
5. V. Phé, O. Cussenot, and M. Rouprêt Methylated genes as potential biomarkers in prostate cancer BJU Int 105 2010 1364
6. C. Jerónimo, R. Henrique, and M.O. Hoque A quantitative promoter methylation profile of prostate cancer Clin Cancer Res 10 2004 8472
7. G.H. Kang, S. Lee, and H.J. Lee Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia J Pathol 202 2004 233
8. M. Truong, B. Yang, and D. Jarrard Towards the detection of prostate cancer in urine: a critical analysis J Urol 189 2013 422
9. S. Jarmalaite, F. Jankevicius, and K. Kurgonaite Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer Oncology 75 2008 145
10. R. Maruyama, S. Toyooka, and K.O. Toyooka Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features Clin Cancer Res 8 2002 514
11. S. Yegnasubramanian, J. Kowalski, and M.L. Gonzalgo Hypermethylation of CpG islands in primary and metastatic human prostate cancer Cancer Res 64 2004 1975
12. J. Ellinger, P.J. Bastian, and T. Jurgan CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer Urology 71 2008 161
13. N. Konishi, M. Nakamura, and M. Kishi DNA hypermethylation status of multiple genes in prostate adenocarcinomas Jpn J Cancer Res 93 2002 767
14. L. Delgado-Cruzata, G.W. Hruby, and K. Gonzalez DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer DNA Cell Biol 31 2012 187
15. E. Rosenbaum, M.O. Hoque, and Y. Cohen Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy Clin Cancer Res 11 2005 8321
16. P.J. Bastian, J. Ellinger, and L.C. Heukamp Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy Eur Urol 51 2007 665
17. L. Liu, K.J. Kron, and V.V. Pethe Association of tissue promoter methylation levels of APC, TGFB2, HOXD3 and RASSF1 with prostate cancer progression Int J Cancer 129 2011 2454
18. M.O. Hoque, O. Topaloglu, and S. Begum Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects J Clin Oncol 23 2005 6569
19. M. Roupret, V. Hupertan, and D.R. Yates Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage Clin Cancer Res 13 2007 1720
20. S.R. Payne, J. Serth, and M. Schostak DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection Prostate 69 2009 1257
21. T. Wu, E. Giovannucci, and J. Welge Measurement of GSTP1 promoter methylation in bodily fluids may complement PSA screening: a meta-analysis Br J Cancer 105 2011 65
22. C. Chao, M. Chi, and M. Preciado Methylation markers for prostate cancer prognosis: a systematic review Cancer Causes Control 24 2013 1615